A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck
AstraZeneca agreed to partner two important oncology assets – Lynparza and selumetinib – with Merck after disappointing Imfinzi MYSTIC data. Merck will pay $1.6bn up front to get its hands on a PARP inhibitor, even though it previously owned one.
You may also be interested in...
The company stopped the Phase III ADAURA study for Tagrisso early due to overwhelming efficacy and the US FDA approved selumetinib in a rare pediatric disease.
The company will depend on Keytruda for growth after spinning out some franchises, but executives argued during its Q4 earnings call that there will be much more to Merck than the cancer blockbuster.
Datamonitor report highlights big pharma’s licensing trends from last five years, and finds UK firm top on numbers of deals, but Merck & Co put up most money.